Lanreotide acetateProduct ingredient for Lanreotide

Name
Lanreotide acetate
Drug Entry
Lanreotide

Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, Ipsen Pharmaceuticals as lanreotide acetate, and marketed as Somatuline. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.

Accession Number
DBSALT001238
Structure
Synonyms
Not Available
UNII
IEU56G3J9C
CAS Number
Not Available
Wikipedia
Lanreotide
Predicted Properties
Not Available